Your Health, We Care

Home >Drug List>Odevixibat
  • Odevixibat
  • Odevixibat

Odevixibat(LuciOdevi)

Another NameBylvay, 奥维昔巴特

IndicationsIt is indicated for the treatment of cholestatic pruritus in patients aged 3 months and older with progressive familial intrahepatic cholestasis (PFIC) and patients aged 12 months and older with Alagi

Specs

  • 400mg*30 caps
  • Reg No.12 L 1278/24
  • Inspection NO.3155-24
  • Dosage Formcapsule
  • Indate24 months
  • Get in touch for a free consultation
  • WhatsApp

    Telegram name: Vira

  • Name: LUCIUS

    No.:0085253923643

Warm tips:Please purchase and use the medication under pharmacist guidance as the outer packaging is for reference only and the information is intended for professionals.
Introduction of Odevixibat

As an oral IBAT inhibitor manufactured by Lucius Pharmaceuticals, this medication provides a targeted treatment option for patients with rare liver diseases and holds favorable clinical application value.

Medicine-related columns

Instructions of Odevixibat

Lucius Related Certificates

137-Odevixibat Test Report_proc.jpg

Certificate of Analysis

12L1278_24 Odevixibat Approval_proc.jpg

Drug Approval Certificate

Active Ingredient

The active ingredient is odevixibat, an inhibitor of the ileal bile acid transporter (IBAT).

Indicated Population

It is indicated for patients with progressive familial intrahepatic cholestasis (PFIC) aged 3 months and older, and patients with Alagille syndrome (ALGS) aged 12 months and older.

Dosage and Administration

Administer orally once daily in the morning with food.

For PFIC patients: The initial dose is 40 mcg/kg, which can be increased to 120 mcg/kg based on treatment response.

For ALGS patients: The recommended dose is 120 mcg/kg.

Reference: Dosage and Administration of Odevixibat

Usage in Special Populations

Pregnant women: Use with caution, as this drug may cause fetal cardiac malformations.

Lactating women: Monitor fat-soluble vitamin levels during treatment.

Pediatric patients: The safety and efficacy of this drug have been established.

Patients with hepatic insufficiency: Use with caution.

Storage Conditions

Store the medication at room temperature, and avoid exposure to high temperatures and humid environments.

Pharmacokinetics

In terms of pharmacokinetics, odevixibat has extremely low oral absorption, with plasma concentrations mostly below the limit of detection. Co-administration with food can further reduce its absorption.

FDA,2025.03